{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:49:50Z","timestamp":1791931790240,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021954","name":"Tour de Cure Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejca.2024.114101","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:26:22Z","timestamp":1715084782000},"page":"114101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases"],"prefix":"10.1016","volume":"205","author":[{"given":"Ines","family":"Pires da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Serra-Bellver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanti","family":"Andhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Burnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Aya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan W.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorja","family":"Braden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114101_bib1","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114101_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2024.114101_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.114101_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114101_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114101_bib6","series-title":"New England Journal of Medicine","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","author":"Wolchok","year":"2017"},{"key":"10.1016\/j.ejca.2024.114101_bib7","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"September 27","author":"Larkin","year":"2019"},{"key":"10.1016\/j.ejca.2024.114101_bib8","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"April 22","author":"Long","year":"2018"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2024.114101_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)","volume":"39","author":"Long","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.114101_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ejca.2024.114101_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti\u2013PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2024.114101_bib12","article-title":"Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma","volume":"40","author":"Da Silva","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114101_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2024.114101_bib14","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"2","key":"10.1016\/j.ejca.2024.114101_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114101_bib16","doi-asserted-by":"crossref","unstructured":"D.B. Rubin Inference Missing Data Biom 63 1976 581 592 .","DOI":"10.1093\/biomet\/63.3.581"},{"issue":"2","key":"10.1016\/j.ejca.2024.114101_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients With advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.114101_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri981","article-title":"Hepatic T cells and liver tolerance","volume":"3","author":"Crispe","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.ejca.2024.114101_bib19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/82161","article-title":"Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance","volume":"6","author":"Limmer","year":"2000","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejca.2024.114101_bib20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.22395","article-title":"Mechanism of T cell tolerance induction by murine hepatic Kupffer cells","volume":"48","author":"You","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejca.2024.114101_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ejca.2024.114101_bib22","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4161\/onci.21176","article-title":"Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth","volume":"1","author":"Fujimura","year":"2012","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejca.2024.114101_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ejca.2024.114101_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"52","key":"10.1016\/j.ejca.2024.114101_bib25","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"LJ","year":"2020","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.ejca.2024.114101_bib26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T Cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.ejca.2024.114101_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205012","article-title":"VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer Types-A meta-analysis","volume":"15","author":"Conway","year":"2023","journal-title":"Cancers"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T21:23:58Z","timestamp":1726089838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S0959804924007573"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114101","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114101"}}